Silo Pharma (NASDAQ:SILO) Upgraded at Wall Street Zen
by Renee Jackson · The Cerbat GemWall Street Zen upgraded shares of Silo Pharma (NASDAQ:SILO – Free Report) to a sell rating in a report issued on Saturday.
Silo Pharma Trading Up 1.9%
NASDAQ SILO opened at $0.60 on Friday. The company has a market cap of $2.67 million, a P/E ratio of -0.51 and a beta of 0.29. The company has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $1.09. Silo Pharma has a 12-month low of $0.41 and a 12-month high of $4.50.
Silo Pharma (NASDAQ:SILO – Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.02 million for the quarter. Silo Pharma had a negative return on equity of 84.88% and a negative net margin of 6,420.83%.
Silo Pharma Company Profile
Silo Pharma Inc operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems.
Featured Stories
- Five stocks we like better than Silo Pharma
- How to Invest in the FAANG Stocks
- These 3 Undervalued Stocks Could Surge as Value Rotation Nears
- What is a Low P/E Ratio and What Does it Tell Investors?
- Tilray Shares Blazing: What’s Behind the 55% Rally This Month?
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up